Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study; [Atriyal Fibrilasyon Hastalarında Gerçek Yaşam Antikoagülan Tedavi Tercihlerinin Değerlendirilmesi: Çok Merkezli ROTA Çalışması Verileri]

ArticleAçık Erişim

Özet

Objective: Oral anticoagulant therapy is the cornerstone of atrial fibrillation management to prevent stroke and systemic embolism. However, there is limited real-world information regarding stroke and systemic embolism prevention strategies in patients with atrial fibrillation. The aim of the ROTA study is to obtain the real-world data of anticoagulant treatment patterns in patients with atrial fibrillation. Materials and Methods: The ROTA study is a prospective, multicenter, and observational study that included 2597 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January 2021 and May 2021. Results: The median age of the study population was 72 years (range: 22-98 years) and 57.4% were female. The median CHA2DS2-VASc and HAS-BLED scores were 4 (range: 0-9) and 1 (range: 0-6), respectively. Vitamin K antagonists and direct oral anticoagulants were used in 15.9% and 79.4% of patients, respectively. The mean time in therapeutic range was 52.9% for patients receiving vitamin K antagonists, and 76% of those patients had an inadequate time in therapeutic range with <70%. The most common prescribed direct oral anticoagulants were rivaroxaban (38.1%), apixaban (25.5%), and edoxaban (11.2%). The rate of overuse of vitamin K antagonists and direct oral anticoagulants was high (76.1%) in patients with low stroke risk, and more than one-fourth of patients on direct oral anticoagulant therapy were receiving a reduced dose of direct oral anticoagulants. Among patients who were on direct oral anticoagulant treatment, patients with apixaban treatment were older, had higher CHA2DS2VASc and HAS-BLED scores, and had lower creatinine clearance than the patients receiving other direct oral anticoagulants. Conclusions: The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial fibrillation. © 2023 Turkish Society of Cardiology. All rights reserved.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/12337Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.5543/tkda.2022.98455Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKocabaş, Umut
dc.contributor.authorErgin, Işıl
dc.contributor.authorYavuz, Veysel
dc.contributor.authorMurat, Selda
dc.contributor.authorÖzdemir, Ibrahim
dc.contributor.authorGenç, Ömer
dc.contributor.authorAltın, Cihan
dc.contributor.authorTüner, Haşim
dc.contributor.authorMeriç, Bengisu Keskin
dc.contributor.authorÇoner, Ali
dc.contributor.authorYüce, Elif İlkay
dc.contributor.authorBoyraz, Bedrettin
dc.contributor.authorAslan, Onur
dc.contributor.authorDal, Ahmet
dc.contributor.authorŞen, Taner
dc.contributor.authorİbişoğlu, Ersin
dc.contributor.authorErdoğan, Aslan
dc.contributor.authorÖzgeyik, Mehmet
dc.contributor.authorDemir, Mevlüt
dc.contributor.authorBilgel, Ziya Gökalp
dc.contributor.authorŞengör, Büşra Güvendi
dc.contributor.authorUrgun, Örsan Deniz
dc.contributor.authorDoğduş, Mustafa
dc.contributor.authorTekin, Deniz Dilan Naki
dc.contributor.authorÇakal, Sinem
dc.contributor.authorÇayırlı, Sercan
dc.contributor.authorGüler, Arda
dc.contributor.authorKarabulut, Dilay
dc.contributor.authorDalgıç, Onur
dc.contributor.authorUzman, Osman
dc.contributor.authorMurat, Bektaş
dc.contributor.authorŞahin, Şeyda
dc.contributor.authorKarabulut, Umut
dc.contributor.authorKıvrak, Tarık
dc.contributor.authorCoşgun, Muharrem Said
dc.contributor.authorÖzyurtlu, Ferhan
dc.contributor.authorKaplan, Mehmet
dc.contributor.authorÖzçalık, Emre
dc.date.accessioned2026-10-18T20:27:15.100808877Z
dc.date.available2026-10-18T20:27:15.100808877Z
dc.date.issued2023
dc.description.abstractObjective: Oral anticoagulant therapy is the cornerstone of atrial fibrillation management to prevent stroke and systemic embolism. However, there is limited real-world information regarding stroke and systemic embolism prevention strategies in patients with atrial fibrillation. The aim of the ROTA study is to obtain the real-world data of anticoagulant treatment patterns in patients with atrial fibrillation. Materials and Methods: The ROTA study is a prospective, multicenter, and observational study that included 2597 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January 2021 and May 2021. Results: The median age of the study population was 72 years (range: 22-98 years) and 57.4% were female. The median CHA2DS2-VASc and HAS-BLED scores were 4 (range: 0-9) and 1 (range: 0-6), respectively. Vitamin K antagonists and direct oral anticoagulants were used in 15.9% and 79.4% of patients, respectively. The mean time in therapeutic range was 52.9% for patients receiving vitamin K antagonists, and 76% of those patients had an inadequate time in therapeutic range with <70%. The most common prescribed direct oral anticoagulants were rivaroxaban (38.1%), apixaban (25.5%), and edoxaban (11.2%). The rate of overuse of vitamin K antagonists and direct oral anticoagulants was high (76.1%) in patients with low stroke risk, and more than one-fourth of patients on direct oral anticoagulant therapy were receiving a reduced dose of direct oral anticoagulants. Among patients who were on direct oral anticoagulant treatment, patients with apixaban treatment were older, had higher CHA2DS2VASc and HAS-BLED scores, and had lower creatinine clearance than the patients receiving other direct oral anticoagulants. Conclusions: The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial fibrillation. © 2023 Turkish Society of Cardiology. All rights reserved.
dc.identifier.doi10.5543/tkda.2022.98455
dc.identifier.eissn1308-4488
dc.identifier.endpage96
dc.identifier.issn1016-5169
dc.identifier.issue2
dc.identifier.pmid36916815
dc.identifier.scopus2-s2.0-85150311273
dc.identifier.startpage88
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/12337
dc.identifier.volume51
dc.language.isoen
dc.publisherTurkish Society of Cardiology
dc.relation.ispartofTurk Kardiyoloji Dernegi Arsivi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectanticoagulation
dc.subjectAtrial fibrillation
dc.subjectdirect oral anticoagulants
dc.subjectstroke
dc.subjectsystemic embolism
dc.subjectAdministration, Oral
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAnticoagulants
dc.subjectDabigatran
dc.subjectEmbolism
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectProspective Studies
dc.subjectPyridones
dc.subjectRivaroxaban
dc.subjectVitamin K
dc.subjectYoung Adult
dc.subjectacetylsalicylic acid
dc.subjectamiodarone
dc.subjectanticoagulant agent
dc.subjectantivitamin K
dc.subjectapixaban
dc.subjectbeta adrenergic receptor blocking agent
dc.subjectclopidogrel
dc.subjectdigoxin
dc.subjectdiltiazem
dc.titleReal-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study; [Atriyal Fibrilasyon Hastalarında Gerçek Yaşam Antikoagülan Tedavi Tercihlerinin Değerlendirilmesi: Çok Merkezli ROTA Çalışması Verileri]
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus6
rdl.citation.trdizin2
rdl.departmentİZMİR EKONOMİ ÜNİVERSİTESİ
rdl.departmentKÜTAHYA SAĞLIK BİLİMLERİ ÜNİVERSİTESİ
rdl.departmentT.C. SAĞLIK BAKANLIĞI
rdl.departmentUŞAK ÜNİVERSİTESİ
rdl.departmentGAZİANTEP ÜNİVERSİTESİ
rdl.departmentESKİŞEHİR OSMANGAZİ ÜNİVERSİTESİ
rdl.departmentEGE ÜNİVERSİTESİ
rdl.departmentBAŞKENT ÜNİVERSİTESİ
rdl.departmentERZİNCAN BİNALİ YILDIRIM ÜNİVERSİTESİ
rdl.departmentAYDIN ADNAN MENDERES ÜNİVERSİTESİ
rdl.departmentSAĞLIK BİLİMLERİ ÜNİVERSİTESİ
rdl.departmentFIRAT ÜNİVERSİTESİ
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexTRDIZIN
rdl.source.indexPUBMED